The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | Promising clinical trials for multiple myeloma: KarMMa, CARTITUDE and EVOLVE
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses promising clinical trials in cellular therapies for multiple myeloma. The Phase II trial KarMMa (NCT03361748) reproduced the results from the Phase I trial with a global cohort. The study investigated idecabtagene vicleucel (bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma. The idecabtagene vicleucel treatment showed a significant clinical response in previously treated multiple myeloma patients and also indicated 20 months of progression-free survival. Other promising trials are CARTITUDE-1 (NCT03548207) and EVOLVE (NCT03430011) which show similar efficacy for JNJ-68284528 and JCARH125 with low toxicity. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
